Table 1.
Characteristics of the study cohort.
| Variable | Number | miR-223 expression, number (%) | P a value | |
|---|---|---|---|---|
| Low | High | |||
| Total | 450 | 285 | 165 | |
| Age (years) | 0.399 | |||
| ≤40 | 52 (11.56%) | 36 (8.00%) | 16 (3.56%) | |
| 40–60 | 330 (73.33%) | 210 (46.67%) | 120 (26.67%) | |
| >60 | 68 (15.11%) | 39 (8.67%) | 29 (6.44%) | |
| Menopausal status | 0.438 | |||
| pre | 229 (50.89%) | 149 (33.11%) | 80 (17.78%) | |
| post | 221 (49.11%) | 136 (30.22%) | 85 (18.89%) | |
| Differentiation | 0.811 | |||
| II | 248 (55.11%) | 155 (34.44%) | 93 (20.67%) | |
| III | 117 (26.00%) | 77 (17.11%) | 40 (8.89%) | |
| Missing | 85 (18.89%) | 53 (11.78%) | 32 (7.11%) | |
| Tumor size (cm) | 0.369 | |||
| ≤2 | 210 (46.67%) | 131 (29.11%) | 79 (17.56%) | |
| 2–5 | 211 (46.89%) | 133 (29.56%) | 78 (17.33%) | |
| >5 | 20 (4.44%) | 13 (2.89%) | 7 (1.56%) | |
| Missing | 9 (2.00%) | 8 (1.78%) | 1 (0.22%) | |
| Lymph node status | 0.539 | |||
| Negative | 252 (56.00%) | 153 (34.00%) | 99 (22.00%) | |
| Positive | 198 (44.00%) | 132 (29.33%) | 66 (14.67%) | |
| ER | 0.622 | |||
| Negative | 255 (56.67%) | 164 (36.44%) | 91 (20.22%) | |
| Positive | 195 (43.33%) | 121 (26.89%) | 74 (16.44%) | |
| PR | 0.195 | |||
| Negative | 298 (66.22%) | 195 (43.33%) | 103 (22.89%) | |
| Positive | 152 (33.78%) | 90 (20.00%) | 62 (13.78%) | |
| HER2 | 0.233 | |||
| Negative | 248 (55.11%) | 151 (33.56%) | 97 (21.56%) | |
| Positive | 202 (44.89%) | 134 (29.78%) | 68 (15.11%) | |
| TNM stage | 0.784 | |||
| I | 139 (30.89%) | 84 (18.67%) | 55 (12.22%) | |
| II | 246 (54.67%) | 157 (34.89%) | 89 (19.78%) | |
| III | 50 (11.11%) | 34 (7.56%) | 16 (3.56%) | |
| Missing | 15 (3.33%) | 10 (2.22%) | 5 (1.11%) | |
| Molecular subtype b | 0.635 | |||
| Luminal A | 99 (22.00%) | 58 (12.89%) | 41 (9.11%) | |
| Luminal B | 108 (24.00%) | 72 (16.00%) | 36 (8.00%) | |
| HER2-enriched | 93 (20.67%) | 61 (13.56%) | 32 (7.11%) | |
| Triple-negative | 150 (33.33%) | 94 (20.89%) | 56 (12.44%) | |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
a
Based on Pearson’s χ2 test; Fisher’s exact test was used when needed.
b
Definitions of subtypes: Luminal A (ER- and/or PR-positive, HER2-negative, PR high expression, and Ki-67 low expression), Luminal B (ER- and/or PR-positive, HER2-positive; ER-and/or PR-positive, HER2-negative, and Ki-67 high expression or PR low expression), HER2-enriched (ER- and PR-negative, HER2-positive), and triple-negative (ER-negative, PR-negative, and HER2-negative).